Skip to main
OMER

Omeros (OMER) Stock Forecast & Price Target

Omeros (OMER) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Omeros is predicted to experience growth in the coming years, with a strong financial outlook and promising development programs for complement-mediated diseases, cancers, and addictive or compulsive disorders. Recent developments, such as the approval and launch of YARTEMLEA and progress in reimbursement infrastructure, show potential for rapid demand acceleration and efficient conversion from clinical interest to utilization, making this an opportune time for potential investment. However, potential risks include clinical and regulatory, partnership, financial, commercial, legal and intellectual property, and market share risks, as well as scrutiny of Omidria royalties outside of the US and the current high treatment cost of Omeros' products.

Bears say

Omeros is facing challenges with their newly approved TA-TMA therapy, as there is limited clinical data supporting its effectiveness and competition from other treatments. The permanent product-specific J-code from CMS is a positive development, but it does not change the lack of data and potential reimbursement issues that may arise. Additionally, the expected regulatory decision from the EMA in mid-2026 and early utilization trends will be important to monitor, as well as any management commentary on initial launch metrics and commercial infrastructure as disclosed on upcoming earnings calls.

Omeros (OMER) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Omeros and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Omeros (OMER) Forecast

Analysts have given Omeros (OMER) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Omeros (OMER) has a Strong Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Omeros (OMER)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.